New Analysis Reveals Foreign Countries’ Flawed Value Assessments Undervalue Innovative Medicines by up to 94%
Outdated Cost-Effectiveness Analysis (CEA) Methodology Abroad Can Delay Access to Life-Saving Medicines for Patients in the U.S. and Globally and Disincentivize Future Innovation
New Study Reveals Widespread Concern over Prescription Price Controls, Costs, and Access
86 percent of respondents shared concerns that state-run Prescription Drug Affordability Boards (PDABs) will limit treatment options; 51 percent said medicines prescribed by their doctor were denied by their insurer
NPLB Gets Animated: Roadmap to Patient Affordability and Innovation
Insurance Reform Needed to Cover Prescribed Medicines without High Out-of-Pocket Costs
“Abbie” Video Highlights Need for Insurance Reforms that Lower Out-of-Pocket Costs
“If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable.”
We’re building support across the biotech ecosystem
BECOME A FIRST RESPONDER & THOUGHT PARTNER
Sign up to receive action alerts. Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.